You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer
|
|---|---|
| Published in |
Cancer Nanotechnology, June 2018
|
| DOI | 10.1186/s12645-018-0040-x |
| Pubmed ID | |
| Authors |
Cian M. McCrudden, John W. McBride, Joanne McCaffrey, Emma M. McErlean, Nicholas J. Dunne, Vicky L. Kett, Jonathan A. Coulter, Tracy Robson, Helen O. McCarthy |
| Abstract |
Recent approvals of gene therapies by the FDA and the EMA for treatment of inherited disorders have further opened the door for assessment of nucleic acid pharmaceuticals for clinical usage. Arising from the presence of damaged or inappropriate DNA, cancer is a condition particularly suitable for genetic intervention. The RALA peptide has been shown to be a potent non-viral delivery platform for nucleic acids. This study examines the use of RALA to deliver a plasmid encoding inducible nitric oxide synthase (iNOS) as an anti-cancer treatment. The physiochemical properties of the RALA/DNA nanoparticles were characterized via dynamic light scattering and transmission electron microscopy. The nanoparticles were labelled with fluorophores and tracked over time using confocal microscopy with orthogonal sections to determine cellular location. In vitro studies were employed to determine functionality of the nanoparticles both for pEGFP-N1 and CMV-iNOS. Nanoparticles were injected intravenously into C57/BL6 mice with blood and serum samples analysed for immune response. PC3-luc2M cells were injected into the left ventricle of SCID mice followed by treatment with RALA/CMV-iNOS nanoparticles to evaluate the tumour response in a metastatic model of prostate cancer. Functional cationic nanoparticles were produced with gene expression in PC-3 prostate cancer cells. Furthermore, repeated administrations of RALA/DNA nanoparticles into immunocompetent mice did not produce any immunological response: neutralization of the vector or release of inflammatory mediators. RALA/CMV-iNOS reduced the clonogenicity of PC-3 cells in vitro, and in an in vivo model of prostate cancer metastasis, systemically delivered RALA/CMV-iNOS significantly improved the survival of mice. These studies further validate RALA as a genetic cargo delivery vehicle and iNOS as a potent therapy for the treatment of cancer. |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 10 | 53% |
| Ireland | 3 | 16% |
| France | 1 | 5% |
| Unknown | 5 | 26% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 68% |
| Scientists | 4 | 21% |
| Science communicators (journalists, bloggers, editors) | 2 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 23% |
| Researcher | 11 | 21% |
| Student > Master | 7 | 13% |
| Student > Bachelor | 4 | 8% |
| Other | 1 | 2% |
| Other | 4 | 8% |
| Unknown | 14 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 13% |
| Medicine and Dentistry | 7 | 13% |
| Biochemistry, Genetics and Molecular Biology | 6 | 11% |
| Agricultural and Biological Sciences | 5 | 9% |
| Chemistry | 5 | 9% |
| Other | 7 | 13% |
| Unknown | 16 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2019.
All research outputs
#2,223,159
of 23,085,832 outputs
Outputs from Cancer Nanotechnology
#6
of 169 outputs
Outputs of similar age
#49,121
of 330,319 outputs
Outputs of similar age from Cancer Nanotechnology
#1
of 2 outputs
Altmetric has tracked 23,085,832 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 169 research outputs from this source. They receive a mean Attention Score of 2.7. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,319 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them